Abstract
Due to sedentary lifestyle and rising prevalence of obesity, patients with general population and those who are infected with chronic hepatitis B are found to have metabolic dysfunction associated steatotic liver disease (MASLD). Both chronic hepatitis B virus (HBV) infection and MASLD can damage hepatocytes in their own way, but concomitant HBV-MASLD has its own clinical implications. Cherry on top is the presence of diabetes mellitus, hypertension or obesity which added more chances of unfavorable outcomes in these patients. In this article, we comment on the article by Wang et al published in the recent issue. This article provides a comprehensive overview of the complex interaction between HBVMASLD, HBV alone and MASLD alone patients. We discuss key findings from recent studies, including the promising outcomes observed in patients with concurrent HBV and MASLD, warrants further research. The insights presented here offer renewed understanding of this complex interaction.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 100968 |
| Number of pages | 1 |
| Journal | World Journal of Hepatology |
| Volume | 17 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2025 |
Keywords
- Chronic hepatitis B virus infection
- Liver fibrosis
- Metabolic syndrome
- Obesity
- Steatotic liver disease